Clinical Trial ImbalanceThe CM24 + nivolumab + gem/nab-paclitaxel vs gem/nab-paclitaxel cohort was impacted by informative censoring of the control arm which led to an imbalance in the number of patients in the active and control arms.
Resource Requirement For DevelopmentNT219 is Phase 2 ready though company likely needs additional resources to advance this program.
Unsuitable Cohort For AnalysisThe gem/nab-paclitaxel cohort was impacted by informative censoring of the control arm which led to an imbalance in the number of patients in the active and control arms, which made this cohort of patients unsuitable for analysis.